Axa S.A. Purchases 43,333 Shares of Stryker Corporation $SYK

Axa S.A. increased its position in shares of Stryker Corporation (NYSE:SYK) by 33.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 173,884 shares of the medical technology company’s stock after acquiring an additional 43,333 shares during the period. Axa S.A.’s holdings in Stryker were worth $68,794,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the company. Mid American Wealth Advisory Group Inc. bought a new position in shares of Stryker in the second quarter worth $26,000. Elevation Point Wealth Partners LLC purchased a new position in Stryker during the second quarter worth about $28,000. Sachetta LLC increased its stake in Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the last quarter. Kilter Group LLC purchased a new stake in shares of Stryker in the 2nd quarter valued at about $29,000. Finally, Howard Hughes Medical Institute bought a new stake in shares of Stryker during the 2nd quarter valued at about $29,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 3.0%

Shares of SYK stock opened at $353.28 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The business has a 50-day moving average of $368.03 and a 200 day moving average of $379.21. The stock has a market capitalization of $135.10 billion, a PE ratio of 46.42, a P/E/G ratio of 2.58 and a beta of 0.89. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the company posted $2.87 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 522,118 shares of company stock valued at $185,381,932 in the last quarter. Company insiders own 5.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SYK. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research note on Friday, November 14th. UBS Group set a $408.00 price objective on shares of Stryker in a research report on Monday, October 13th. Wells Fargo & Company upped their target price on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Truist Financial raised their price target on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research report on Friday, November 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $448.00 price target on shares of Stryker in a research note on Friday, November 14th. Twelve research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $433.78.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.